Treatment of intrabony periodontal defects using rhFGF‐2 in combination with deproteinized bovine bone mineral or rhFGF‐2 alone: A 6‐month randomized controlled trial
Authors:
Open Access
- 13 February 2019
- journal article
- research article
- Published by Wiley in Journal of Clinical Periodontology
- Vol. 46 (3) , 332-341
Abstract
Aim: To evaluate the use of recombinant human fibroblast growth factor (rhFGF)‐2 in combination with deproteinized bovine bone mineral (DBBM) compared with rhFGF‐2 alone, in the treatment of intrabony periodontal defects.Materials and Methods: Patients with periodontitis who had received initial periodontal therapy and had intrabony defects of ≥ 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rhFGF‐2 + DBBM (test) or rhFGF‐2 alone (control). Clinical parameters and a patient‐reported outcome measure (PROM) were evaluated at baseline and at 3 and 6 months postoperatively.Results: Twenty‐two sites in each group were evaluated. A significant improvement in clinical attachment level (CAL) from baseline was observed in both groups at 6 months postoperatively. CAL gain was 3.16 ± 1.45 mm in the test group and 2.77 ± 1.15 mm in the control group, showing no significant difference between groups. Radiographic bone fill was significantly greater in the test group (47.2%) than in the control group (29.3%). No significant difference in PROM between groups was observed.Conclusions: At 6 months, no significant difference in CAL gain or PROM between the two treatments was observed, although combination therapy yielded an enhanced radiographic outcome.Keywords
Funding Information
- Osteology Foundation (17‐136)
This publication has 46 references indexed in Scilit:
- Adsorption of Enamel Matrix Proteins to a Bovine‐Derived Bone Grafting Material and Its Regulation of Cell Adhesion, Proliferation, and DifferentiationJournal of Periodontology, 2012
- Potential impact of surgical periodontal therapy on oral health‐related quality of life in patients with periodontitis: a pilot studyJournal of Clinical Periodontology, 2011
- Four-year results following treatment of intrabony periodontal defects with an enamel matrix derivative alone or combined with a biphasic calcium phosphateClinical Oral Investigations, 2011
- Effects of concomitant use of fibroblast growth factor (FGF)-2 with beta-tricalcium phosphate (β-TCP) on the beagle dog 1-wall periodontal defect modelBiochemical and Biophysical Research Communications, 2010
- FGF-2 Stimulates Periodontal RegenerationJournal of Dental Research, 2010
- Periodontal Tissue Regeneration Using Fibroblast Growth Factor -2: Randomized Controlled Phase II Clinical TrialPLOS ONE, 2008
- Endpoints in periodontal trials: the need for an evidence‐based research approachPeriodontology 2000, 2004
- Clinical outcomes following treatment of human intrabony defects with GTR/bone replacement material or access flap aloneJournal of Clinical Periodontology, 2004
- Enamel matrix proteins in the regenerative therapy of deep intrabony defectsJournal of Clinical Periodontology, 2002
- The Plaque Control RecordJournal of Periodontology, 1972